ReviewEndocrinology and metabolism (Seoul, Korea)2022
Update from the 2022 World Health Organization Classification of Thyroid Tumors: A Standardized Diagnostic Approach.
Review in Endocrinology and metabolism (Seoul, Korea), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 163 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
163 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- SEOM-GETNE-TTCC Clinical guideline thyroid cancer (2023).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Guideline
- Radioactive iodine therapy for thyroid cancer coexisting with Hashimoto's thyroiditis: a systematic review and meta-analysis.The British journal of radiology · 2024Pooled it
- Prognosis of Poorly Differentiated Thyroid Carcinoma: A Systematic Review and Meta-Analysis.Endocrinology and metabolism (Seoul, Korea) · 2024Pooled it
- UCHL5 suppresses thyroid carcinoma progression via ZRANB1 stabilization and ferroptosis regulation.Cancer biology & therapy · 2026Article
- Phenotype-driven cascade screening in a Syrian family with clinically consistent multiple endocrine neoplasia type 2A.JCEM case reports · 2026Article
- Conventional sonographic phenotype of thyroid oncocytic neoplasms: a pathology-confirmed comparative study.Journal of ultrasound · 2026Article
- Immune checkpoints and immunoregulation in metabolic diseases and cancers: pathological mechanisms and therapeutic potential.Signal transduction and targeted therapy · 2026Review
- Comprehensive Review of Extracellular Vesicles in Thyroid Cancer: From Methodological Approaches to Biological Functions and Clinical Applications.International journal of molecular sciences · 2026Review
- Extrathyroidal extension is independently associated with cervical lymph node metastasis in pediatric papillary thyroid carcinoma.Archives of endocrinology and metabolism · 2026Article
- Value of TERT promoter mutations for early outcomes in papillary thyroid cancer.Endocrine-related cancer · 2026Article
- Detection of preoperative serum trace elements in thyroid tumors.Gland surgery · 2026Article
- Malignancy Risk Within Hyperfunctioning Thyroid Nodules: Clinicopathologic Features and Diagnostic Implications.Diagnostics (Basel, Switzerland) · 2026Article
- Portable Multispectral Optoelectronic System for Thyroid Cancer Detection.Sensors (Basel, Switzerland) · 2026Article
- Survival outcomes, metastatic patterns, and local invasion in oncocytic papillary thyroid carcinomas and oncocytic carcinomas: A retrospective cohort study.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- Observational
- MAPK pathway inhibitors enhance radioiodine sensitivity in anaplastic thyroid carcinoma through promoting NIS expression and ARF4-mediated NIS membrane transport.Scientific reports · 2026Article
- Time to euthyroidism and its predictors among thyrotoxicosis patients on antithyroid drugs at tertiary hospitals, Western Oromia, Ethiopia: a retrospective cohort study.Thyroid research · 2026Article
- Predictive factors of non-invasive follicular thyroid neoplasm with papillary-like nuclear features: A single-center study.Turkish journal of surgery · 2026Article
- A review of spontaneous bone metastases in domestic and laboratory animals.Journal of bone oncology · 2026Review
- P53 loss and BRAF V600E mutation suggest potentially divergent pathways to aggressiveness in high grade differentiated thyroid carcinoma.Discover oncology · 2026Article
103 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The fifth edition of the World Health Organization (WHO) histologic classification of thyroid neoplasms released in 2022 includes newly recognized tumor types, subtypes, and a grading system. Follicular cell-derived neoplasms are categorized into three families (classes): benign tumors, low-risk neoplasms, and malignant neoplasms. The terms "follicular nodular disease" and "differentiated high-grade thyroid carcinoma" are introduced to account for multifocal hyperplastic/neoplastic lesions and differentiated thyroid carcinomas with high-grade features, respectively. The term "Hürthle cells" is replaced with "oncocytic cells." Invasive encapsulated follicular and cribriform morular variants of papillary thyroid carcinoma (PTC) are now redefined as distinct tumor types, given their different genetic alterations and clinicopathologic characteristics from other PTC subtypes. The term "variant" to describe a subclass of tumor has been replaced with the term "subtype." Instead, the term "variant" is reserved to describe genetic alterations. A histologic grading system based on the mitotic count, necrosis, and/or the Ki67 index is used to identify high-grade follicular-cell derived carcinomas and medullary thyroid carcinomas. The 2022 WHO classification introduces the following new categories: "salivary gland-type carcinomas of the thyroid" and "thyroid tumors of uncertain histogenesis." This review summarizes the major changes in the 2022 WHO classification and their clinical relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.